C 24 H 18 F 2 N 2 O 3 S, monoclinic, P21/c (no. 14), a = 15.180(5) Å, b = 10.221(3) Å, c = 13.556(4) Å, β = 106.628(4)°, V = 2015.3(10) Å 3 , Z = 4, Rgt(F) = 0.0530, wR ref (F 2 ) = 0.1342, T = 173(2) K.
CrysAlis PRO [1] , SHELX [2, 3] 
Source of material
The starting materials 3-pyridinecarboxaldehyde (1.07 g, 10.0 mmol), 2-fluorobenzaldehyde (1.24 g, 10.0 mmol) and 4-piperidone hydrate hydrochloride (1.35 g, 10.0 mmol), were dissolved in acetic acid (20 mL). This mixture was passed through by dry HCL gas for 30 min resulting in a clear solution. After stirring at room temperature for about 24 h [monitored by thin-layer chromatography (TLC)], the precipitate was collected and washed with cold acetone. The precipitate was added into 100 mL water, and then aqueous Na 2 CO 3 solution was added until pH value was adjusted to about 7. The mixture was filtered and subsequently washed by water to provide yellow precipitates. The precipitates were purified on silica gel by column chromatography using methanol/petroleum ether/EtOAc (10:10:1, v/v/v) as the eluent to afford a yellow intermediate. Next, the yellow intermediate (0.59 g, 2.0 mmol), and 4-fluorobenzenesulfonyl chloride (0.43 g, 2.2 mmol) were mixed in 50 mL of dichloromethane. Two drops of pyridine were added and the mixture was stirred for about 6 h at room temperature, and inspected by TLC. The precipitate was collected, washed with water and recrystallized from dichloromethane/methanol (1:1, v/v) to get light yellow crystals of title compound. The anti-inflammatory activities of title compound were evaluated by inhibition of LPS-induced NO secretion on RAW264.7 cells. Pyrrolidine dithiocarbamate (PDTC, 30 M) was used as a reference standard. In preliminary experiments, the title compound had no significant toxicity at 6.0 M on mouse RAW264.7 macrophages. RAW264.7 cells were pretreated with 30 M of PDTC or with 6.0 M of title compound for 2.0 h. After treatment with LPS (1.0 g/mL) for 22 h, the collected culture media were centrifuged at 1000 rpm for 10 min. The expression levels of NO secretion in the media were determined by ELISA with an ELISA kit (eBioScience, San Diego, CA). The experiment was carried out in triplicate.
Experimental details
All H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C-H) = 0.99 Å (methylene), U iso (H) = 1.2Ueq(C) and d(C-H) = 0.95 Å (aromatic), U iso (H) = 1.2Ueq(C).
Comment
Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadien-3,5-dion, a natural product from Curcuma longa, has been proved to show anti-inflammatory, anti-tumor, antioxidant, antibacterial activities. Its clinical application was limited because of its low bioactivities, poor aqueous solubility and false positive problem [4] . In order to overcome these defects, a series of novel curcumin analogues have been reported, such as (3E,5E)-3,5-bis(arylidene)-4piperidone derivatives (BAPs). They were previously synthesized as better antitumor and anti-inflammatory agents [5, 6] . BAPs contain two α,β-unsaturated keto groups, and show greater predilection or sequential interaction for biothiols in tumors rather than normal cell [7] . In a previous study, some strong electron-withdrawing substituent groups (Such as -NO 2 , -CN, -CF 3 ) were assigned to both sides of BAPs. Their antitumor and anti-inflammatory activities were improved to different extent. Some crystal structure and bioactivity of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl) benzonitrile (BAP-1), (3E,5E)-3,5-bis(4-cyanobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one (BAP-2), (3E,5E)-3,5-bis(3-nitrobenzylidene)-1-((4-(trifluoromethyl) phenyl) sulfonyl)piperidin-4-one (BAP-3) were reported [8] [9] [10] .
If changing one side of BAPs to 3-pyridine substituents, while another side of BAPs is substituted by fluoro in ortho position, dissymmetric BAPs will be generated [11] . Adding a N-phenylsulfonyl moiety, the desired and improved antitumor activities and anti-inflammatory activity of BAPs could be found. In this study, we report herein crystal structure and anti-inflammatory activity of (3E,5E)-3-(2fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one.
Single-crystal structure analysis reveals that there is only one BAP molecule in the asymmetric unit of the title crystal structure (cf. the figure) . Bond lengths and angles are all in the expected ranges. The central 3,5-bis(arylidene)-4-piperidone expand both sides in a linear fashion, and pyridyl and 2-fluorobenzylidene on both sides of central piperidone adopt the E stereochemistry of the olefinic double bonds [12] . The dihedral angles between pyridyl and central piperidone is 12.5(4)°, while the dihedral angles between 2fluorobenzylidene and central piperidone is 53.1(2)°. In addition, the N-phenylsulfonyl substituents are going to stretch in the direction of the carbonyl group of central piperidone.
The molecule looks like an "organic clip" [13, 14] . The dihedral angles between N-phenylsulfonyl group and piperidone ring is 22.8(2)°. In title compound, the peripheric heteroatoms (Such as F, N, O, S) can act as hydrogen bonding acceptors for bioactive molecules with the aim of creating more potent antitumor activities and anti-inflammatory activity [15] .
It is known to all that the production of pro-inflammatory cytokines, such as NO, TNF-α and IL-6, can indicate the degree of inflammation [16] . In our study, the effect of title compound on NO production in RAW264.7 cells induced by LPS was examined by ELISA. PDTC was used as a reference standard. After treatment with PDTC, the express rate for NO production in RAW264.7 cells was 68.32 ± 2.69%. After treatment with title compound, the express rate of NO production was significantly increased, which could reach 49.19 ± 1.50%. The result showed that title compound displayed potential inhibitory effects on LPS-induced NO secretion than PDTC.
